Trust & Transparency
References
The published evidence base behind our educational content.
Representative literature
The references below are representative of the peer-reviewed studies, registries and reviews that inform our Knowledge Centre. Individual articles carry their own inline citations.
1
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist
Coskun T, et al. · Cell Metabolism, 2022
2
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. · New England Journal of Medicine, 2023
3
Retatrutide in type 2 diabetes: a randomised, phase 2 trial
Rosenstock J, et al. · The Lancet, 2023
4
Triple agonism and metabolic-associated steatotic liver disease
Sanyal AJ, et al. · Nature Medicine, 2024
5
Anti-obesity drug discovery: advances and challenges
Müller TD, et al. · Nature Reviews Drug Discovery, 2022
6
Incretin hormones: their role in health and disease
Nauck MA, Meier JJ. · Diabetes, Obesity and Metabolism, 2018
7
ClinicalTrials.gov registry entries for retatrutide (LY3437943)
U.S. National Library of Medicine. · clinicaltrials.gov
8
Efficacy and safety of co-agonists of incretin receptors
Frías JP, et al. · Diabetes Care, 2021
Citations are provided for scientific reference only. Their inclusion does not imply that any product on this site is a treatment or is approved for human use.